ZVRA - ZEVRA THERAPEUTICS, INC.
IEX Last Trade
7.84
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:26:37 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.51%
PREVIOUS CLOSE
CHG
CHG%
$7.84
0.66
0.08%
Fundamental analysis
25%
Profitability
8%
Dept financing
27%
Liquidity
75%
Performance
30%
Performance
5 Days
0.59%
1 Month
-7.01%
3 Months
12.01%
6 Months
94.72%
1 Year
73.27%
2 Year
55.49%
Key data
Stock price
$7.84
DAY RANGE
$7.84 - $8.50
52 WEEK RANGE
$4.34 - $9.76
52 WEEK CHANGE
$70.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Travis C. Mickle
Region: US
Website: kempharm.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kempharm.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. Its product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH)
Recent news